# Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

> **NCT07322783** · PHASE2 · RECRUITING · sponsor: **Qingdao Central Hospital** · enrollment: 60 (estimated)

## Conditions studied

- EGFR Positive Non-small Cell Lung Cancer
- MET Amplification

## Interventions

- **DRUG:** • Drug: Savolitinib • Drug: Osimertinib Mesylate Tablets

## Key facts

- **NCT ID:** NCT07322783
- **Lead sponsor:** Qingdao Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07322783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07322783, "Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07322783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*